Episode Details

On this episode we feature the CEO of Resolution Therapeutics, Amir Hefni. Throughout his career, Amir has held roles with global powerhouses such as BMS, Ipsen, & Novartis, before transitioning to small biotech with Resolution in 2023.

Resolution's pipeline of regenerative macrophage therapies originates from research out of Edinburgh University. With potential across inflammatory & fibrotic diseases, the team are currently focused on patients with end-stage liver cirrhosis who otherwise only have transplantation as a treatment option.

Tune in to hear more about Resolution's ongoing ph1/2 trials & what to look out for from them in 2026. We also discussed Amir's findings during the transition from big pharma to small biotech, plus the pro's & con's of building in biotech in The UK.